Ananda S, Wong H, Faragher I, Jones I T, Steele M, Kosmider S, Desai J, Tie J, Field K, Wong R, Tran B, Bae S, Gibbs P
Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.
Intern Med J. 2016 Feb;46(2):166-71. doi: 10.1111/imj.12916.
The Australian National Bowel Cancer Screening Program (NBCSP) has been offering age-based faecal occult blood testing since 2006. With the rapid expansion of this programme, the NBCSP will ultimately offer biennial screening to all 50-74 years old by 2020. Participation rates remain low. Previous reports have described an increased proportion of earlier stage cancers in patients with NBCSP-detected tumours.
Data on consecutive patients enrolled into a prospective, comprehensive, multidisciplinary database at six Victorian hospitals were examined. Clinicopathologic and outcome data were compared for NBCSP and symptomatic presentation patients.
We identified 3743 patients that presented with colorectal cancer (CRC) at participating hospitals since May 2006. Of 1930 patients aged between 50 and 70 years, 141 (7.3%) had a NBCSP detected cancer, 1441 (74.7%) presented with symptoms and 266 (13.8%) were diagnosed through screening outside of the NBCSP. Based on the American Society of Anaesthesiology score, the NBCSP patients were fitter. They had an earlier stage of diagnosis and were more likely to be female and less likely to have lymphovascular invasion or to present as an emergency. NBCSP detected patients had a lower rate of recurrence (HR 0.17, P = 0.0001) and fewer deaths (HR 0.19, P = 0.005).
Patients with NBCSP-detected CRC have a markedly reduced risk of CRC recurrence and death compared with patients with a symptomatic presentation. The dominant driver of this appears to be earlier stage at diagnosis. Increased promotion of the impact of the NBCSP, including data related to the survival impact, should be undertaken to increase participation rates and achieve further survival gains.
自2006年以来,澳大利亚国家肠癌筛查计划(NBCSP)一直在提供基于年龄的粪便潜血检测。随着该计划的迅速扩展,到2020年,NBCSP最终将为所有50至74岁的人群提供两年一次的筛查。参与率仍然很低。先前的报告描述了在NBCSP检测出肿瘤的患者中,早期癌症的比例有所增加。
对维多利亚州六家医院纳入前瞻性、综合性、多学科数据库的连续患者的数据进行了检查。比较了NBCSP患者和有症状表现患者的临床病理及预后数据。
我们确定了自2006年5月以来在参与研究的医院中出现结直肠癌(CRC)的3743例患者。在1930例年龄在50至70岁之间的患者中,141例(7.3%)通过NBCSP检测出患有癌症,1441例(74.7%)有症状表现,266例(13.8%)是通过NBCSP以外的筛查被诊断出来的。根据美国麻醉医师协会评分,NBCSP患者身体状况更好。他们诊断时处于更早阶段,更有可能是女性,发生淋巴管侵犯或急诊就诊的可能性更小。NBCSP检测出的患者复发率较低(风险比0.17,P = 0.0001),死亡人数较少(风险比0.19,P = 0.005)。
与有症状表现的患者相比,NBCSP检测出患有CRC的患者CRC复发和死亡风险显著降低。这一现象的主要驱动因素似乎是诊断时处于更早阶段。应加强对NBCSP影响的宣传,包括与生存影响相关的数据,以提高参与率并进一步提高生存率。